June 2025
1. MCCLELLAND S 3RD, Fleming-Hall E, Smith TK, Onyewadume L, et al
   Establishing Feasibility of the Navigator-assisted Hypofractionation (NAVAH) Program to Address Radiation Therapy Access Disparities Facing African-Americans With Prostate Cancer.
   Am J Clin Oncol. 2025;48:325-326.
   

   >> Share

   
   
2. CARMELI Y, Shpatz Y, Oren-Ivry I, Mansano A, et al
   Effect of Continuous Nutritionist-led Guidance on Bowel Preparation in Patients Undergoing Prostate Stereotactic Body Radiation Treatment With Endorectal Spacing: A Prospective Pilot Trial.
   Am J Clin Oncol. 2025;48:314-318.
   

   >> Share

   
   May 2025
3. SABBAH A, Delouya G, Laskine M, Taussky D, et al
   Metabolic Plasticity in Prostate Cancer: The Warburg Effect and Its Clinical Relevance.
   Am J Clin Oncol. 2025 May 15. doi: 10.1097/COC.0000000000001215.
   

   >> Share

   
   January 2025
4. SMITH RP, Mohammed MA, Beriwal S, Benoit RM, et al
   Prostate Brachytherapy With Cs-131: Long-term Results Compared With Published Stereotactic Body Radiotherapy Data.
   Am J Clin Oncol. 2025;48:34-37.
   

   >> Share

   
   November 2024
5. QURESHI Z, Fatima E, Safi A, Khanzada M, et al
   Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer: A Narrative Review.
   Am J Clin Oncol. 2024 Nov 25. doi: 10.1097/COC.0000000000001159.
   

   >> Share

   
   October 2024
6. OHAEGBULAM KC, Post CM, Farris PE, Garzotto M, et al
   Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer: Results From a Prospective Pilot Study.
   Am J Clin Oncol. 2024 Oct 30. doi: 10.1097/COC.0000000000001151.
   

   >> Share

   
   September 2024
7. RITTER AR, Prasad RN, Jhawar SR, Bazan JG, et al
   Hypofractionated Radiation Therapy: A Cross-sectional Survey Study of US Radiation Oncologists.
   Am J Clin Oncol. 2024;47:434-438.
   

   >> Share

   
   August 2024
8. MELLGARD G, Saffran N, Chakrani Z, McCroskery S, et al
   Performance Status and End-of-Life Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Androgen Receptor Targeted Therapy.
   Am J Clin Oncol. 2024 Aug 1. doi: 10.1097/COC.0000000000001115.
   

   >> Share

   
   July 2024
9. LEHRER S, Rheinstein PH
   Salbutamol, a Short Acting Beta-2 Agonist, Reduces Risk and Improves Prognosis of Prostate Cancer.
   Am J Clin Oncol. 2024 Jul 8. doi: 10.1097/COC.0000000000001134.
   

   >> Share

   
   February 2024
10. CHAKRANI Z, Mellgard G, Saffran N, McCroskery S, et al
    Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy.
    Am J Clin Oncol. 2024 Feb 12. doi: 10.1097/COC.0000000000001087.
    

    >> Share

    
    January 2024
11. JANOPAUL-NAYLOR JR, Koo A, Qian DC, McCall NS, et al
    Physician Assessment of ChatGPT and Bing Answers to American Cancer Society's Questions to Ask About Your Cancer.
    Am J Clin Oncol. 2024;47:17-21.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share